Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag Publisert: 24.04.2023 Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB Publisert: 22.04.2023 Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million Publisert: 29.03.2023 Navamedic ASA: Q4 2022 financial results Publisert: 16.02.2023 Navamedic ASA: Invitation to 2022 4th quarter presentation Publisert: 13.02.2023 Navamedic ASA: Q3 2022 financial results Publisert: 01.11.2022 FørsteForrige1314151617NesteSiste
Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag Publisert: 24.04.2023
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB Publisert: 22.04.2023
Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million Publisert: 29.03.2023
